The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

The Directors: Ben Ho Park and Suresh Ramalingam discuss tough times, uncertainty, and resilience
“If you’re going to be an oncologist, we look at the glass 5% full, not 95% empty.”

Cancer Policy

After stormy Senate hearing, Trump offers tepid support for RFK Jr. while Kennedy family members call for his ouster

Trump administration releases MAHA report on children’s health

Vinay Prasad regains role as FDA chief medical and scientific officer

FDA advances rare disease drug development with new evidence principles

As House committee gives NIH a small raise, cancer groups hope to maintain bipartisan support

The departure (and return) of Vinay Prasad

Clinical Roundup

Rybrevant + Lazcluze block resistance, extend survival in first-line EGFR-mutated NSCLC, phase III trial shows

Tagrisso + chemo demonstrate OS benefit in EGFR-mutated NSCLC, phase III trial shows

Padcev + Keytruda reach primary endpoint for some bladder cancers, phase III trial shows

NeXT Personal MRD test predicts NSCLC outcomes, phase III trial shows

Checkpoint therapy breakthrough sparks new vaccine

Pre- and post-surgery immunotherapy combination shows promise for mesothelioma, Johns Hopkins-led study shows

In The Clinic
Conversation with The Cancer Letter

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

Trials & Tribulations

The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account